Open in interactive viewer → charts, metric popovers & call review

Protalix: The $25 Million Question Behind a $75 Million Headline

Elfabrio goods revenue grew 14% and gross margin ticked to ~64% — yet for the third straight quarter, every analyst on the call was really asking one thing: how predictable is this revenue stream, and why won't management say?
PLX · Earnings Call · 2026-11-10

Protalix: The $25 Million Question Behind a $75 Million Headline

Protalix opened its Q3 2026 call the way it has opened every call for a year: with the year-to-date number, not the quarter. Nine-month revenue of $75.6 million against $43.6 million is a 73% headline — except $25 million of it was a one-time milestone from Chiesi, disclosed in the same breath. Strip the milestone and sales of Elfabrio-driven goods revenue went from $43.1 million to $49.1 million, up 14%. That is the real growth rate of this business, and it is a perfectly respectable one — just not the one the press release leads with.

What actually improved

The quarter's genuinely good news sits below the revenue line. Cost of revenues fell $0.4 million to $7.9 million on $21.8 million of goods revenue, implying a gross margin near 64% — above the 61.0% trailing figure carried in the fundamentals file, which still reflects the June quarter because the latest 10-Q predates this call.

GM ~64% in Q3 vs 61.0% trailing

CFO Gilad Mamlok was unusually direct about why — and about whether it lasts. “I suggest to look at the year always, the first 9 months. And yes, you can refer it as a baseline because like we explained, revenues to Chiesi are increasing and that improves the gross margin.” — Gilad Mamlok, Senior Vice President and Chief Financial Officer · 2026-11-10 Asked whether the mix shift is structural, CEO Dror Bashan gave the cleanest answer of the call: “Yes. The Elfabrio margin is higher.” — Dror Bashan, President and CEO · 2026-11-10

So the machinery is working: higher-margin product, less lumpy Pfizer manufacturing noise, a lower cost base. The offset is that the savings are being fed straight into the clinic. R&D rose $2.4 million year-over-year to $6.9 million, driven by subcontractor spend on the RELEASE study, partially offset by a $1 million grant under Israel's R&D law — a recurring line the company has leaned on since at least the March quarter, when taxes on income and the R&D law both sat near the top of the keyword list.

R&D as a share of revenue

One line item deserves more attention than it got: taxes on income swung to a $0.7 million expense from a $0.1 million benefit, driven by GILTI — global intangible low-taxed income. That is the price of being profitable on paper while earning in Israel, and it has now appeared as a named keyword in two consecutive quarters.

The question nobody wants to answer

Here is the tension that defines this call. Ram Selvaraju of H.C. Wainwright has now asked essentially the same question three quarters running: how predictable is this revenue? In November 2025 he asked whether the company anticipated "further predictability of the royalty-based revenue recognition"; in May 2026 he asked about "the core determinants of the cadence"; on Tuesday he asked whether the quarter represented "a potential new plateau."

I can say that we expect this increase to continue. We're not going to provide guidance now. But as we provided guidance for this year at the beginning of this year, we are going to do the same for 2027 once we publish our annual results.

Gilad Mamlok, Senior Vice President and Chief Financial Officer · 2026-11-10

The reason a baseline is hard to give was spelled out three months ago, and it is the single most important disclosure in this whole sequence. “We did have a nice quarter from Chiesi, which reflects also their growth of the business, but mainly reflects their inventory management.” — Gilad Mamlok, Senior Vice President and Chief Financial Officer · 2026-08-12 Protalix books revenue when it ships to Chiesi; Chiesi books revenue when a patient infuses. Between those two events sits a private Italian company's inventory policy, which Protalix cannot forecast and is contractually limited from disclosing. Twelve months ago Mamlok was still telling investors “we have good predictability in terms of our revenues, and we do hope to give some more visibility also in our annual report” — Gilad Mamluk, Senior Vice President and Chief Financial Officer (CFO) · 2025-11-13 — a promise the annual report has not yet kept in the direction of more granularity.

The every-four-weeks EU label, approved in March, is the genuine cure for lumpiness because it drives patient volume rather than channel stocking. But asked for conversion data, the answer remained qualitative: “We think from what we see so far, the execution is good and is progressing” — Dror Bashan, President and CEO · 2026-11-10, with Mamlok adding only that there is "an accelerated penetration in terms of number of patients treated in Europe." Asked twice whether half of patients could eventually convert, Bashan declined: “It's certainly a significant portion of the patients.” — Dror Bashan, President and CEO · 2026-11-10

PRX-115: adjectives replacing numbers

The Phase I individual patient data presented at ACR Convergence 2026 shows PRX-115 plasma levels measurable out to 85 days — support for the frequent dosing argument, and evidence of a real immunogenicity advantage over existing uricases. Note what happened to the vocabulary, though. Last quarter the company's keyword profile was dominated by methotrexate-sparing arms and responder-rate arithmetic; this quarter the language has collapsed into good outcome and significant portion. When Selvaraju pressed on best-in-class positioning versus existing drugs, the answer was:

We hope to get a good outcome, which clearly will be beneficial for these patients in uncontrolled gout, meaning, let's say, less frequent dosing... once in 6 weeks with good immunogenicity and safety profile. Don't ask me to give you a number. Let's call it a good outcome.

Dror Bashan, President and CEO · 2026-11-10

To be fair, the timeline held: enrollment is expected to close next quarter and the Phase II top line remains "second half of next year," exactly as guided in May. That is unusual discipline for a company that has historically pushed its pipeline to the right. The market is also warming to this kind of data — ACR20 response was a top-25 keyword across the entire global tape this quarter, and immunology reporters like IMVT and ROIV were talking about patients on paid drug. Protalix is now in that conversation, even if its evidence today is convenience-claim data rather than a placebo-controlled win.

The pipeline asset that stopped being mentioned

The quiet story is pipeline in rare renal diseases — specifically PRX-119, which has now been deferred three consecutive calls. In March, Bashan hoped for a decision "by the end of Q2." In May, the same. On Tuesday: “I know it's being delayed, but we assume we'll take decision this quarter what we do with this program.” — Dror Bashan, President and CEO · 2026-11-10 The third deferral is not fatal, but it is a pattern, and it is why the named asset has dropped out of the company's keyword profile entirely after appearing prominently through 2024.

What protects the story is the balance sheet. Cash and deposits of $48.5 million against zero debt and zero warrants, up $7.8 million sequentially — a rise that occurred despite a negative free cash flow picture in the prior quarter. A $207 million market cap with roughly two times revenue and no solvency risk buys the company patience.

Price to Revenue ~2.3x

Meanwhile the equity has quietly put on 21% over 90 days — up 17 weeks in a straight line — against a lifetime return of minus 96%. When a stock down that much starts rising into a report, the market is buying the pipeline, not the P&L. The bet is that a Fabry market the CEO sizes at roughly $3.2 billion by 2031, plus a uricase market the CFO watched grow from $1.3 billion in 2025 toward $1.6 billion, is worth more than a 14% goods-revenue growth rate.

The bottom line

Protalix had a good quarter and gave a deliberately non-committal call. Margins are better, the every-four-weeks label is working in Europe, cash is sufficient, and PRX-115's evidence base for less frequent dosing in a high unmet need indication improved. What has not improved is visibility: the revenue line belongs to a partner's inventory decisions, the pipeline's answer is two years away, and a third deferral of PRX-119 suggests internal bandwidth is being rationed. The company's financial flexibility — a phrase it has used since mid-2026 — is now genuinely real rather than aspirational. That is the strongest thing on the call, and it is not on the income statement.